Metabolic research

Tirzepatide

Lyophilized metabolic research compound

Tirzepatide is a dual GIP / GLP-1 receptor agonist reference point in metabolic research and comparative incretin pharmacology.

98.8%-99.5% Lyophilisiertes Pulver 30 mg

Available certificate of analysis

This product has an available COA with reported batch details and test results.

Open available COA

Menge

Packungsgröße

Zurücksetzen

Catalog updates and a welcome offer

Confirm an optional email signup to receive a single-use 10% welcome code.

Get catalog updates

Nur für Laborforschungszwecke. Nicht für den menschlichen oder veterinärmedizinischen Gebrauch bestimmt. Nicht zur Diagnose, Behandlung, Heilung, Linderung oder Vorbeugung von Krankheiten bestimmt.

Lagerung

Verschlossen, kalt, trocken und vor Hitzeschwankungen geschützt aufbewahren. Bestätigen Sie die produktspezifische Lagerung bei der Ankunft.

Versandhinweise

Verpackt für Transportstabilität mit Bestellunterstützung für Routen bei warmem Wetter.

Batch reference

Batch-linked certificate support is available through the documentation desk.

Forschungskontext

Tirzepatide Forschungsprofil

Tirzepatide is a dual GIP and GLP-1 receptor agonist used extensively in incretin and metabolic pharmacology research. Experimental work examines receptor activation, cyclic-AMP signaling, receptor balance, pharmacokinetics, glucose regulation, lipid markers, and downstream metabolic endpoints. It is commonly compared with GLP-1-only compounds and with newer multi-receptor molecules such as retatrutide. Buyers typically select tirzepatide when the study design specifically needs a well-characterized dual-incretin reference without glucagon-receptor activity. A large human literature exists for the pharmaceutical molecule, but those findings do not verify the composition, sterility, safety, or performance of a separate research-use product.

Molecular class

39-residue acylated dual incretin agonist

Sequence / composition

A modified 39-amino-acid peptide containing non-canonical residues and a C20 fatty-diacid moiety.

Research design note

The engineered construct is studied for differentiated GIPR and GLP-1R signaling and longer circulating exposure.

Vorgeschlagener Mechanismus

Dual agonism at GIPR and GLP-1R, two class B G-protein-coupled receptors that signal largely through cyclic AMP. Proposed effects include glucose-dependent insulin secretion, altered glucagon signaling, delayed gastric emptying through GLP-1 pathways, and central appetite-related signaling.

In Studien berichtete Effekte

Receptor and animal studies report enhanced incretin signaling, improved glucose control, reduced food intake, and reduced body mass.
Controlled human trials reported substantial reductions in glycated hemoglobin and body weight across studied populations.
Frequently reported study effects include nausea, diarrhea, vomiting, constipation, and other gastrointestinal events.

Häufige Forschungsendpunkte

GIPR and GLP-1R potency, cyclic AMP, insulin and glucagon response, gastric-emptying markers, glucose, HbA1c, lipids, food intake, body mass, pharmacokinetics, and tolerability.

Evidenz und Grenzen

Extensive receptor, animal, and controlled human evidence exists for regulated tirzepatide products. Catalog material is not represented as equivalent to an approved pharmaceutical product.

External reading

Literature for context—not product proof.

Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.

Tirzepatide PubMed literature search

Support and documentation

Questions about this product?

Where can I find product documentation?

Open the direct COA link on this page. For other batch documents, contact support with the product name and any relevant order or batch reference.

How can I compare pack options?

Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.

Keep comparing

Compare other catalog records.

Explore related research materials. These are not a combined-use recommendation.